GlassScriptPhysician profile
Daniel Roy Clang
NPI 1346215266
$569.71
in general payments reported to CMS, 2019-2025
18 companies · $33.74 in 2025
The $33.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $36.42 · 2022: $90.14 · 2023: $32.11 · 2024: $142 · 2025: $33.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $117.39 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $93.01 | 2019 | |
| Glaxosmithkline, LLC. | $37.58 | 2024-2025 | Arexvy, Shingrix, Bexsero |
| Janssen Pharmaceuticals, INC | $37.20 | 2019 | |
| Corium, LLC | $35.72 | 2022-2023 | Azstarys |
| Lilly USA, LLC | $33.21 | 2023-2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.86 | 2020-2024 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $25.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.41 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.22 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.34 | 2024 | Caplyta |
| Novo Nordisk INC | $14.70 | 2022 | |
| Strongbridge US INC. | $14.03 | 2019 | |
| Amgen INC. | $13.61 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $13.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.03 | 2022 | |
| Genentech USA, INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Clang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.